CSIMarket
 
Supernus Pharmaceuticals inc   (NASDAQ: SUPN)
Other Ticker:  
 
 
Price: $38.6500 $0.72 1.898%
Day's High: $38.66 Week Perf: -2.1 %
Day's Low: $ 37.66 30 Day Perf: 3.09 %
Volume (M): 312 52 Wk High: $ 40.28
Volume (M$): $ 12,059 52 Wk Avg: $32.37
Open: $37.76 52 Wk Low: $25.53



 Market Capitalization (Millions $) 2,165
 Shares Outstanding (Millions) 56
 Employees 652
 Revenues (TTM) (Millions $) 642
 Net Income (TTM) (Millions $) 43
 Cash Flow (TTM) (Millions $) 27
 Capital Exp. (TTM) (Millions $) 1

Supernus Pharmaceuticals Inc
Supernus Pharmaceuticals is a pharmaceutical company that specializes in the development and commercialization of treatments for central nervous system (CNS) disorders. The company was founded in 2005 and is headquartered in Rockville, Maryland, USA.

Supernus has a diverse portfolio of products in various stages of development. The company's leading products include Oxtellar XR, a treatment for partial onset seizures in adults and children, and Trokendi XR, a treatment for migraines and epilepsy. Additionally, Supernus is developing other treatments for CNS disorders, including ADHD, schizophrenia, and depression.

The company's management team has extensive experience in the pharmaceutical industry and has a track record of successful drug development and commercialization. The company has a robust intellectual property portfolio, including patents for its lead products.

Supernus has a strong partnership with the FDA and has received several FDA approvals for its products. The company also focuses on the development of drugs with improved delivery methods, including sustained-release formulations and transdermal patches.

In addition to its drug development pipeline, Supernus has a strong financial position with significant cash reserves and revenue growth. The company also has partnerships with several other pharmaceutical companies to develop and commercialize their products.

Overall, Supernus Pharmaceuticals is a well-established pharmaceutical company with a strong focus on innovation and drug development for CNS disorders. The company's diverse portfolio of products, strong management team, and financial position make it a promising player in the pharmaceutical industry.


   Company Address: 9715 Key West Avenue Rockville 20850 MD
   Company Phone Number: 838-2500   Stock Exchange / Ticker: NASDAQ SUPN


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABBV        0.04% 
BMY   -6.31%    
REGN   -7.15%    
TEVA   -3.6%    
VRTX   -6.8%    
VTRS   -3.11%    
• View Complete Report
   



Product Service News

Resubmission of SPN-830 NDA A Step Forward in Parkinsons Disease Management

Published Thu, Aug 1 2024 8:30 PM UTC

In a significant development within the field of neurology, Supernus Pharmaceuticals, Inc. has announced the resubmission of its New Drug Application (NDA) for SPN-830, an innovative apomorphine infusion device aimed at providing continuous treatment for motor fluctuations in patients with Parkinson s disease (PD). This announcement, made on August 1, 2024, highlights Supern...

Clinical Study

' Supernus Pharmaceuticals Reports Promising Interim Results from Phase 2a Study of SPN-817, A Novel Acetylcholinesterase Inhibitor for Epilepsy Treatment

Published Thu, May 23 2024 8:06 PM UTC

Epilepsy, a neurological disorder characterized by recurrent, unprovoked seizures, affects millions of individuals worldwide. Despite numerous available treatments, a significant percentage of patients continue to suffer from uncontrolled seizures, highlighting the dire need for new therapeutic avenues. Supernus Pharmaceuticals, Inc., a company renowned for its innovative ap...

Product Service News

Supernus Pharmaceuticals' SPN-830 Infusion Device Advances in FDA Review: A Potential Breakthrough in Managing Parkinson's Disease 'Off Episodes'

Published Mon, Apr 8 2024 12:01 PM UTC

Supernus Pharmaceuticals, Inc., a biopharmaceutical firm headquartered in Rockville, Maryland, specializing in the development and commercialization of products for the treatment of central nervous system (CNS) diseases, announced new progress regarding the ongoing regulatory procedures of the SPN-830 infusion device. SPN-830, an investigational apomorphine infusion device, ...

Supernus Pharmaceuticals Inc

Thriving Sales Bathe Supernus Pharmaceuticals Inc. as Deficit Woe Takes a Backseat in July to September 2023



Supernus Pharmaceuticals Inc, a biopharmaceutical company specializing in central nervous system (CNS) disease treatments, recently released its financial results for the July to September 2023 period. While the numbers paint a concerning picture, it is essential to analyze the implications of these results and understand how they might shape the company's future.
A Widening Deficit:
One of the primary concerns highlighted in the financial report is Supernus Pharmaceuticals Inc's growing deficit. The company reported a deficit per stock of $-0.29, a notable decline from the positive $0.03 reported a year ago. Additionally, the deficit surged further from $-0.02 per share from the previous financial reporting period. This continuous increase in the deficit raises questions about the company's financial stability and its ability to generate sustainable profits.

Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals Inc reports resilient revenue decline during Q2 2023 earnings season



Supernus Pharmaceuticals Inc, a leading pharmaceutical company, recently released its financial report for the second quarter of 2023. The report highlights a decline in business, resulting in increased losses for the company during this period. Furthermore, revenue experienced a significant decrease compared to the previous year, reflecting various challenges faced by Supernus Pharmaceuticals in the current market.
Financial Analysis:
In the second quarter of 2023, Supernus Pharmaceuticals recorded a loss per share of $-0.02, contrasting with the previous year's figure of $0.14. This decline reflects the challenging market conditions faced by the company, ultimately impacting its financial performance. Additionally, revenue decreased by 20.281% from $170.05 million to $135.56 million in the second quarter of 2023 compared to the same period in the previous year.







Supernus Pharmaceuticals Inc's Segments
Net product sales    96.93 % of total Revenue
Qelbree    35.49 % of total Revenue
GOCOVRI    20.3 % of total Revenue
Oxtellar XR    16.96 % of total Revenue
APOKYN    11.31 % of total Revenue
Trokendi XR    8.72 % of total Revenue
Other    4.15 % of total Revenue
Royalty licensing and other revenues    3.07 % of total Revenue

  Supernus Pharmaceuticals Inc Outlook

On October 25 2023 the Supernus Pharmaceuticals Inc provided following guidance

Supernus Pharmaceuticals, a leading biopharmaceutical company specializing in the development and commercialization of CNS disease tr...





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com